"The Novavax vaccine was developed using protein-based technology instead of mRNA technology. FDA-approved protein-based vaccines have been used widely for decades and include vaccines to prevent hepatitis B and shingles. Novavax is authorized as a two-dose primary series, given three to eight weeks apart, in individuals ages 18 and older.